Background: Although each biomarker (hsCRP, fibrinogen, NT-proBNP, BUN, FBS) is a specific for certain population, incremental value of these biomarkers has not been evaluated in AMI. Therefore, we sought the incremental prognostic value of inflammatory, cardiorenal and metabolic biomarker in AMI. Methods: Three hundred thirty-five consecutive patients with AMI (242 men, 163 ST elevation MI, mean age 63 짹 12) were prospectively enrolled in Infarction Prognosis Study (IPS) registry. At the time of enrollment, hsCRP, fibrinogen, BUN, NT-proBNP and FBS were measured. Subjects were divided into 3 groups based on number of biomarkers were above each cut-off values (hsCRP: 10 mg/L, fibrinogen: 400 mg/dl, BUN: 20 mg/dl, NT-porBNP: 500 pg/ml, FBS: 110 mg/dl)(Group 1: < 2, Group 2: 2-4, Group 3: ��� 4). Mean follow-up duration were 12 month (range, 1 to 24). Results: Of the 335 patients, MACE (cardiac death, non-fatal MI, re-admission due to UA or HF) was developed in 37 patients (11 %). MACE was occurred in 2 (2 %) of 118 patients of group 1, 15 (10 %) of 144 patients of group 2 and 20 (27 %) of 73 patients of group 3 (p< 0.001). Even after adjusting for the conventional risk factors, group 3 had a 5.4-fold higher risk for cardiac events than group 1. (Group 2: HR 2.5 95% CI 0.54–12.2 and Group 3: HR 5.4 95 % CI 1.09–26.5). Conclusion: Combination of inflammatory, cardiorenal and metabolic biomarkers has graded incremental effects in predicting cardiovascular events in patients with AMI, independent of conventional clinical risk factors.